Do analysts rate SURG or PETV?

SurgePays currently has a consensus price target of $3.50, suggesting a potential upside of 1,512.90%. Given SurgePays' stronger consensus rating and higher probable upside, research analysts plainly believe SurgePays is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SURG or PETV more profitable?

SurgePays has a net margin of -64.91% compared to PetVivo's net margin of -902.82%. SurgePays' return on equity of 0.00% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% PetVivo -902.82% -4,813.07% -281.78%

Does the media favor SURG or PETV?

In the previous week, SurgePays had 1 more articles in the media than PetVivo. MarketBeat recorded 3 mentions for SurgePays and 2 mentions for PetVivo. SurgePays' average media sentiment score of 1.24 beat PetVivo's score of 0.49 indicating that SurgePays is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PetVivo 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CTSO or SURG more profitable?

Cytosorbents has a net margin of -31.85% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -31.85% -235.57% -37.88% SurgePays -64.91% N/A -310.16%

Does the media favor CTSO or SURG?

In the previous week, SurgePays had 1 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for SurgePays and 2 mentions for Cytosorbents. SurgePays' average media sentiment score of 1.24 beat Cytosorbents' score of 0.00 indicating that SurgePays is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SurgePays 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RVP or SURG?

SurgePays has a consensus price target of $3.50, suggesting a potential upside of 1,512.90%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than Retractable Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is SURG or LFWD more profitable?

SurgePays has a net margin of -64.91% compared to Lifeward's net margin of -123.66%. SurgePays' return on equity of 0.00% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% Lifeward -123.66% -243.14% -97.39%

Do analysts prefer SURG or OSRH?

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 1,512.90%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SURG or OSRH?

OSR has lower revenue, but higher earnings than SurgePays. OSR is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SurgePays $56.96M 0.10 -$36.07M -$1.94 N/A OSR $2.91M 5.43 -$27.06M -$0.33 N/A

Is SURG or OSRH more profitable?

SurgePays has a net margin of -64.91% compared to OSR's net margin of -363.26%. SurgePays' return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% N/A -310.16% OSR -363.26% -7.24% -5.41%

Does the media prefer SURG or OSRH?

In the previous week, SurgePays had 2 more articles in the media than OSR. MarketBeat recorded 3 mentions for SurgePays and 1 mentions for OSR. SurgePays' average media sentiment score of 1.24 beat OSR's score of 0.70 indicating that SurgePays is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OSR 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SurgePays (SURG) Competitors

$0.22 0.00 (-0.46%)

As of 12:46 PM Eastern

Compare

SURG vs. PETV, CTSO, RVP, LFWD, and OSRH

Should you buy SurgePays stock or one of its competitors? MarketBeat compares SurgePays with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SurgePays include PetVivo (PETV), Cytosorbents (CTSO), Retractable Technologies (RVP), Lifeward (LFWD), and OSR (OSRH).

How does SurgePays compare to PetVivo?

SurgePays (NASDAQ:SURG) and PetVivo (NASDAQ:PETV) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

6.9% of SurgePays shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 10.8% of PetVivo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, SurgePays had 1 more articles in the media than PetVivo. MarketBeat recorded 3 mentions for SurgePays and 2 mentions for PetVivo. SurgePays' average media sentiment score of 1.24 beat PetVivo's score of 0.49 indicating that SurgePays is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PetVivo	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SurgePays has a net margin of -64.91% compared to PetVivo's net margin of -902.82%. SurgePays' return on equity of 0.00% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
PetVivo	-902.82%	-4,813.07%	-281.78%

SurgePays has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

PetVivo has lower revenue, but higher earnings than SurgePays. PetVivo is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.10	-$36.07M	-$1.94	N/A
PetVivo	$1.05M	23.58	-$10.95M	-$0.38	N/A

SurgePays currently has a consensus price target of $3.50, suggesting a potential upside of 1,512.90%. Given SurgePays' stronger consensus rating and higher probable upside, research analysts plainly believe SurgePays is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

SurgePays beats PetVivo on 10 of the 16 factors compared between the two stocks.

How does SurgePays compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and SurgePays (NASDAQ:SURG) are related small-cap companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Cytosorbents has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Cytosorbents has higher earnings, but lower revenue than SurgePays. Cytosorbents is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.63	-$8.20M	-$0.19	N/A
SurgePays	$56.96M	0.10	-$36.07M	-$1.94	N/A

Cytosorbents has a net margin of -31.85% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
SurgePays	-64.91%	N/A	-310.16%

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 7.8% of Cytosorbents shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 1,348.79%. SurgePays has a consensus target price of $3.50, suggesting a potential upside of 1,512.90%. Given SurgePays' higher possible upside, analysts clearly believe SurgePays is more favorable than Cytosorbents.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, SurgePays had 1 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for SurgePays and 2 mentions for Cytosorbents. SurgePays' average media sentiment score of 1.24 beat Cytosorbents' score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SurgePays	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cytosorbents beats SurgePays on 8 of the 15 factors compared between the two stocks.

How does SurgePays compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and SurgePays (NASDAQ:SURG) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

7.6% of Retractable Technologies shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 59.5% of Retractable Technologies shares are held by insiders. Comparatively, 29.1% of SurgePays shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Retractable Technologies has a net margin of -41.11% compared to SurgePays' net margin of -64.91%. SurgePays' return on equity of 0.00% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
SurgePays	-64.91%	N/A	-310.16%

SurgePays has a consensus price target of $3.50, suggesting a potential upside of 1,512.90%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than Retractable Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Retractable Technologies has higher earnings, but lower revenue than SurgePays. Retractable Technologies is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$37.15M	0.54	-$7.01M	-$0.21	N/A
SurgePays	$56.96M	0.10	-$36.07M	-$1.94	N/A

Retractable Technologies has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, SurgePays has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

In the previous week, SurgePays had 3 more articles in the media than Retractable Technologies. MarketBeat recorded 3 mentions for SurgePays and 0 mentions for Retractable Technologies. SurgePays' average media sentiment score of 1.24 beat Retractable Technologies' score of 0.00 indicating that SurgePays is being referred to more favorably in the news media.

Company	Overall Sentiment
Retractable Technologies	Neutral
SurgePays	Positive

Summary

Retractable Technologies and SurgePays tied by winning 8 of the 16 factors compared between the two stocks.

How does SurgePays compare to Lifeward?

SurgePays (NASDAQ:SURG) and Lifeward (NASDAQ:LFWD) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

6.9% of SurgePays shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 29.1% of SurgePays shares are owned by insiders. Comparatively, 1.5% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lifeward has lower revenue, but higher earnings than SurgePays. Lifeward is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.10	-$36.07M	-$1.94	N/A
Lifeward	$22.03M	0.91	-$19.91M	-$19.66	N/A

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 1,512.90%. Lifeward has a consensus price target of $10.00, indicating a potential upside of 40.45%. Given SurgePays' higher possible upside, equities analysts clearly believe SurgePays is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lifeward	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, SurgePays had 2 more articles in the media than Lifeward. MarketBeat recorded 3 mentions for SurgePays and 1 mentions for Lifeward. Lifeward's average media sentiment score of 2.00 beat SurgePays' score of 1.24 indicating that Lifeward is being referred to more favorably in the news media.

Company	Overall Sentiment
SurgePays	Positive
Lifeward	Very Positive

SurgePays has a net margin of -64.91% compared to Lifeward's net margin of -123.66%. SurgePays' return on equity of 0.00% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
Lifeward	-123.66%	-243.14%	-97.39%

SurgePays has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Summary

SurgePays beats Lifeward on 9 of the 15 factors compared between the two stocks.

How does SurgePays compare to OSR?

SurgePays (NASDAQ:SURG) and OSR (NASDAQ:OSRH) are related small-cap companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

OSR has lower revenue, but higher earnings than SurgePays. OSR is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.10	-$36.07M	-$1.94	N/A
OSR	$2.91M	5.43	-$27.06M	-$0.33	N/A

SurgePays has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, OSR has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

SurgePays currently has a consensus price target of $3.50, indicating a potential upside of 1,512.90%. Given SurgePays' stronger consensus rating and higher possible upside, analysts plainly believe SurgePays is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SurgePays has a net margin of -64.91% compared to OSR's net margin of -363.26%. SurgePays' return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	N/A	-310.16%
OSR	-363.26%	-7.24%	-5.41%

6.9% of SurgePays shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 36.9% of OSR shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, SurgePays had 2 more articles in the media than OSR. MarketBeat recorded 3 mentions for SurgePays and 1 mentions for OSR. SurgePays' average media sentiment score of 1.24 beat OSR's score of 0.70 indicating that SurgePays is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OSR	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SurgePays beats OSR on 9 of the 16 factors compared between the two stocks.

Get SurgePays News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SURG vs. The Competition

Export

Metric	SurgePays	Wireless Telecommunication Services Industry	Communication Services Sector	NASDAQ Exchange
Market Cap	$5.48M	$24.78B	$33.58B	$12.66B
Dividend Yield	N/A	3.36%	5.34%	10.03%
P/E Ratio	-0.11	17.73	20.21	25.05
Price / Sales	0.10	12.62	320.53	79.91
Price / Cash	N/A	8.78	19.58	46.71
Price / Book	-0.33	2.91	10.55	6.18
Net Income	-$36.07M	$2.03B	$1.11B	$347.61M
7 Day Performance	-10.33%	-1.36%	1.05%	0.71%
1 Month Performance	-62.12%	-4.36%	-0.42%	-3.75%
1 Year Performance	-91.96%	24.78%	5.49%	20.17%

SurgePays Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SURG SurgePays	3.483 of 5 stars	$0.22 -0.5%	$3.50 +1,512.9%	-91.9%	$5.48M	$56.96M	N/A	40	Positive News
PETV PetVivo	N/A	$0.62 flat	N/A	-14.6%	$23.44M	$1.05M	N/A	20	High Trading Volume
CTSO Cytosorbents	1.9757 of 5 stars	$0.37 +2.8%	$5.38 +1,352.7%	-58.5%	$23.19M	$37.06M	N/A	220	Upcoming Earnings Gap Up
RVP Retractable Technologies	N/A	$0.68 +0.7%	N/A	-11.1%	$20.21M	$37.15M	N/A	240
LFWD Lifeward	2.2103 of 5 stars	$7.04 -1.0%	$10.00 +42.0%	-13.6%	$19.79M	$22.03M	N/A	60	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SURG) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SurgePays (SURG) Competitors